Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Amgn crawled date : 2022 - 09 - 19 save search
Global Central Nervous System Therapeutics Market to Grow at Healthy CAGR Due to Rising Disorder Prevalence & Technical Advancements
Published: 2022-09-19 (Crawled : 21:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -6.97%
H: 7.7%
C: -0.76%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.34%
H: 6.64%
C: -0.06%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.96%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.82%
H: 0.07%
C: -0.61%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.71%
H: 0.2%
C: -0.23%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: -0.69%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.18%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.71%
H: 0.08%
C: -1.72%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.16%
H: 0.56%
C: 0.14%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.98%
H: 0.65%
C: -0.35%
global system therapeutics market
Cancer Biologics Market to record USD 34.97 Bn growth, Evolving Opportunities with Amgen Inc. and AstraZeneca Plc
Published: 2022-09-19 (Crawled : 07:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -8.32%
H: 12.85%
C: 9.85%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.63%
H: 0.14%
C: -3.38%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.52%
H: 0.69%
C: 0.62%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.55%
H: 0.64%
C: 0.39%
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.54%
H: 1.18%
C: 0.94%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.66%
H: 1.6%
C: 1.15%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.14%
H: 0.09%
C: 0.03%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.22%
H: 0.1%
C: 0.05%
cancer market
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published: 2022-09-19 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.52%
H: 0.69%
C: 0.62%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.22%
H: 0.1%
C: 0.05%
biosimilar trial positive
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.